Black patients are more likely to experience adverse cardiovascular outcomes after systemic androgen deprivation therapy (ADT) for prostate cancer, according to a retrospective cohort study involving 3,543 prostate cancer patients treated with the therapy between 2008 and 2021.
The researchers found that the risk for these adverse events was 38 percent increased in Blacks, with the strongest associations seen for incident heart failure, cerebrovascular disease, and peripheral artery disease. Overall, 98 percent of the disparity in adverse event risk between Black and White patients was mediated by the social vulnerability index, specifically the socioeconomic status theme.
“Multilevel targeted interventions tailored to the needs of patients from socioeconomically vulnerable communities are necessary to reduce the disparities in CVD in patients with prostate cancer,” the authors said.
See “Black Patients More Likely to Experience MACE After ADT for Prostate Cancer” (June 20, 2024)
